ALMDP.PA

Medesis Pharma S.A. [ALMDP.PA] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

ALMDP.PA Stock Summary

In the News

ALMDP.PA Financial details

Company Rating
-
Market Cap
6.82M
Income
-
Revenue
-
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
10
Optionable
No
Shortable
Yes
Earnings
17 Apr 2024
P/E
-1.35
Forward P/E
-
PEG
-
P/S
89.36
P/B
-3.54
P/C
-
P/FCF
-
Quick Ratio
0.13
Current Ratio
0.71
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-
EPS next Y
-
EPS next Q
-
EPS this Y
3.28%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
21.29%
Revenue last 5Y
33.87%
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-10.26%
SMA50
-2.78%
SMA100
-16.67%
Inst Own
-
Inst Trans
-
ROA
-144%
ROE
-939%
ROC
194.55%
Gross Margin
-4662%
Oper. Margin
-6858%
Profit Margin
-5842%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.75-2.67
52W High
-
52W Low
-
RSI
40.9
Rel Volume
-
Avg Volume
9.49K
Volume
Perf Week
0%
Perf Month
-12.28%
Perf Quarter
-
Perf Half Y
-14.22%
-
-
-
-
Beta
-0.056
-
-
Volatility
0%, 0.02%
Prev Close
0%
Price
0.35
Change
0%

Something similar

Top by Market Cap
MSF.DE
TSLA
DHR-PB
MIX.JO
VFINX
Same Sector
2696.HK
LASA.NS
AUP.TO
DRMAW
MPLN
Same Price Range
8367.HK
PXS.L
1317.HK
CNFN
0475.HK
Similar Market Cap
CNG.L
QQJG
ADUX.PA
EVE.SW
YGMZ

Company Profile

Healthcare Biotechnology
  • Volume Average 9.49K
  • Market Capitalization 6.82M
  • Employee 10
  • CEO Dr. Jean-Claude Maurel M.D., MHB
  • Headquarters Montpellier,FR
  • IPO Date 2021-02-12
  • Website https://www.medesispharma.com

Medesis Pharma S.A., a clinical development stage biopharmaceutical company, engages in the development of orally administered molecule drug candidates to address unmet medical needs. Its products include NanoLithium (NP03), a clinical stage development product for the treatment of Alzheimer's disease; NanosiRNA DH for the treatment of Huntington's Disease; NU01 Plutonium and NU02 Cesium decorporation products for nuclear decorporation; a radioprotection drug to treat people irradiated following a civil or military nuclear accident (NP02 – NanoManganese); NanosiRNA COVID-19, an antiviral treatment solution for viral diseases; and NanosiRNA Resistant cancers and NanosiRNA Oncolytic virus for the treatment of oncology. The company was founded in 2003 and is based in Montpellier, France.